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Network-Driven Mechanisms of 
Alzheimer’s Disease Pathogenesis
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The pathogenesis of Alzheimer’s disease (AD) has been postulated to preferentially 
impact specific neural networks in the brain. The olfactory system is a well-defined net-
work that has been implicated in early stages of the disease, marked by impairment in 
olfaction and the presence of pathological hallmarks of the disease, even before clinical 
presentation. Discovering the cellular mechanisms involved in the connectivity of pathol-
ogy will provide insight into potential targets for treatment. We review evidence from 
animal studies on sensory alteration through denervation or enrichment, which supports 
the notion of using the olfactory system to investigate the implications of connectivity 
and activity in the spread of pathology in AD.
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iNTRODUCTiON
The olfactory system, used to detect odors in the environment, has been proposed to decrease in 
function due to physiological changes during normal aging (Doty, 2009; Masurkar and Devanand, 
2014). Declines in olfactory function have also been commonly observed in neurodegenerative 
diseases, such as Parkinson’s disease (Hawkes et al., 1997; Doty, 2012), Huntington’s disease (Barresi 
et al., 2012), and frontotemporal dementia (Heyanka et al., 2014). Although some studies suggest 
that anosmia is associated with the presence of Lewy bodies rather than Alzheimer-type pathology, 
declines in olfactory function are commonly researched in Alzheimer’s disease (AD) (Mesholam 
et al., 1998). As well as decreased olfactory function, post mortem studies have demonstrated the 
presence of amyloid-beta (Aβ) and hyperphosphorylated tau (key products in the two major AD 
pathological hallmarks; Attems et al., 2014) in the olfactory system. Olfactory dysfunction can occur 
even at a preclinical stage of the disease (Masurkar and Devanand, 2014), suggesting that the olfac-
tory system and its involvement in normal aging and AD may allow for a unique investigation of 
preclinical detection of AD. There is also some evidence to suggest that other risk factors of AD may 
interact with the olfactory network. For example, apolipoprotein E (apoE), a predictive risk factor 
for AD (Masurkar and Devanand, 2014), may be involved in olfactory function, as apoE knockout 
mice demonstrated poorer olfactory performance when compared to control mice (Nathan et al., 
2004). Further, it has been shown that specific neural networks in the brain may be more vulnerable 
to preferential impacts of neurodegenerative diseases, such as AD (Seeley et al., 2009). Therefore, 
the olfactory system provides an ideal neural network to investigate the specific mechanisms that 
may be involved in olfactory dysfunction in normal aging and AD, as well as selective network-
driven neuronal vulnerability in relation to AD-related pathology. This review aims to examine the 
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involvement of the olfactory system in AD, and the possible role 
of the connectivity and activity of this system in the spread of 
pathology based on the findings from studies altering sensory 
input of the olfactory system.
HUMAN OLFACTORY DYSFUNCTiON iN 
ALZHeiMeR’S DiSeASe
It has been postulated that AD is associated with olfactory dys-
function as the disease progresses. Early-stage AD has been shown 
to result in lower-level deficits in odor detection (threshold sensi-
tivity), as well as higher-order deficits in odor quality perception, 
such as discrimination and identification (Li et  al., 2010). In a 
recent review of behavioral testing in human beings, the major-
ity of studies showed a correlation between cognitive status and 
baseline olfactory test scores (Masurkar and Devanand, 2014). 
Additionally, magnetic resonance imaging has shown deficits in 
odor identification ability that are correlated with smaller hip-
pocampal volume in individuals with mild cognitive impairment 
(MCI) and early AD. However, in this study, hippocampal volume 
was not found to be associated with cognitive impairment test 
scores (Kjelvik et al., 2014). Despite this, there has been a strong 
predictive utility of olfactory tests for progression from normal 
aging to MCI to AD (Masurkar and Devanand, 2014). In support 
of this, it has also been shown that AD and amnestic MCI patients 
display significant deficits in olfactory identification tests when 
compared to healthy elderly people (Bahar-Fuchs et  al., 2011). 
However, regardless of the diagnostic status of the participant, the 
large majority had no subjective complaints of olfactory decline. 
This suggests that although impairments in olfaction may occur in 
preclinical stages of AD, such as amnestic MCI (Yaffe et al., 2006), 
the use of olfactory decline as the sole predictor of progression to 
AD is limited (Bahar-Fuchs et al., 2011). Further, participants in 
experiments who may have preclinical AD-related changes, but 
who may not complain of olfactory impairment, could be errone-
ously classified as “controls” (Masurkar and Devanand, 2014). The 
situation is complicated by the proposition that in healthy adults, 
aging is considered the strongest correlate of olfactory decline 
(Doty, 2009). Thus, further studies on olfactory dysfunction in 
AD are required, particularly to gain a better understanding of 
the cellular mechanisms that operate to induce AD pathogenesis 
in the olfactory system and elsewhere in the brain.
NeUROPATHOGeNeSiS iN THe 
OLFACTORY SYSTeM iN ALZHeiMeR’S 
DiSeASe
Both the olfactory system and areas of the brain with extensive 
connections to the olfactory system demonstrate pathological 
changes, such as Aβ plaques and neurofibrillary tangles (NFTs) 
(Christen-Zaech et al., 2003). The olfactory system is comprised 
of many different components, with the olfactory bulbs (OB) 
located at the base of the frontal lobe in human beings. Axons 
from the OB project to higher order, central structures in the 
primary olfactory cortex via the lateral olfactory tract (Doty, 
2009; see Figure 1). Higher order structures include the anterior 
olfactory nucleus (AON), the piriform cortex (PCX), the anterior 
cortical nucleus of the amygdala, the periamygdaloid cortex, and 
the rostral entorhinal cortex. There are reciprocal relationships 
between these structures, as well as with other higher-order 
structures (Doty, 2009). For example, key efferents of the AON 
project to the ipsilateral OB and olfactory cortex, and also to the 
contralateral bulb and AON (Shipley et  al., 2008). Beyond the 
primary olfactory cortex, neocortical areas, such as the lateral 
entorhinal cortex and the orbitofrontal cortex, receive substantial 
olfactory input (Wilson and Rennaker, 2010). Among mamma-
lian species, the general circuitry of the olfactory–hippocampal 
pathway and its cytoarchitecture are preserved. There are outputs 
from the olfactory system that reach the parahippocampal region 
of the brain, including the perirhinal, parahippocampal, and 
entorhinal cortices (Eichenbaum, 1998). The primary olfactory 
cortex has connections to brain regions, such as the hippocampus 
(Haberly, 2001), which are also involved in AD. In later stages of 
the disease, NFTs are abundant in almost all components of the 
hippocampal formation, despite relatively few Aβ deposits (Braak 
and Braak, 1991). Specifically, hippocampal field CA1 is very 
severely affected by NFTs, whereas field CA3 and the subiculum 
are only somewhat affected (Price et al., 1991). Overall, the olfac-
tory system has substantial connections to areas of the brain that 
are related to memory and display AD pathology.
In addition to hippocampal changes, AD pathological changes 
have also been described in olfactory cortical regions. For exam-
ple, pathological changes that occur in the entorhinal cortex and 
associated neural systems may be responsible for early memory 
deficits in AD (Van Hoesen et al., 1991). Six clear stages related 
to the progression of Alzheimer-related changes have been deter-
mined based on the distribution of NFTs and neuropil threads in 
the brain, with the earliest changes involving the transentorhinal 
region of the cortex (Braak and Braak, 1991). Interestingly, stud-
ies have identified damage to the OB in the earliest stages of AD, 
even preceding damage to the entorhinal cortex (Kovács et al., 
2001). These findings implicate the olfactory system in the early 
stages of disease progression, and also highlight the involvement 
of connectivity, both within the olfactory system and to associ-
ated areas, in AD pathology.
An early study into pathological changes in the olfactory system 
identified a higher number of NFTs and plaques in the olfactory 
cortex of human brains when compared to other brain regions. 
Further, these pathological markers of AD were also observed in 
other brain regions receiving input from the OB (Table 1; Reyes 
et al., 1993). Additional evidence also suggests that AD pathology 
and other related changes are present within higher cortical areas 
involved in olfaction. For example, computational brain imaging 
of MCI patients demonstrated that, over time, the patients who 
progressed to AD showed greater loss of gray matter in all brain 
areas than the MCI patients who remained stable, but the loss 
mainly occurred in the olfactory and polysynaptic hippocampal 
network (Prestia et al., 2010). Furthermore, in the AON, which 
is formed by large multipolar neurons embedded within the 
granule cell layer (GCL) and olfactory tract (Kovács, 2013), NFTs 
and a reduced neuron density have been identified (Esiri and 
Wilcock, 1984). NFTs have also been shown to be present in the 
AON and the parahippocampal gyrus in young (54–63 years of 
FiGURe 1 | Neuronal pathways from olfactory sensory neurons through the olfactory bulb and tract to associated cortical areas. GL = glomerulus, 
Mi = mitral cells.
December 2015 | Volume 7 | Article 2343
Franks et al. Connectivity of Pathology in Alzheimer’s
Frontiers in Aging Neuroscience | www.frontiersin.org
age), non-demented cases. However, with increasing severity of 
dementia, the number and density of tangles increased (Price 
et al., 1991). “Primitive” plaques were found particularly in the 
neocortex and, when dementia became more severe, there was 
a shift from “primitive” or diffuse plaques to “mature” plaques 
(Price et al., 1991). “Mature” plaques were described as having 
amyloid cores (Price et al., 1991), which have been classified as 
dense-cored plaques, in contrast to diffuse plaques (Dickson and 
Vickers, 2001). In addition, small numbers of plaques, as well as 
NFTs, have been found scattered throughout the AON in AD 
cases, but not in age-matched controls (Ohm and Braak, 1987). 
The research demonstrates that in human beings with AD, there 
will likely be a presence of NFTs in higher cortical areas, specifi-
cally the AON, and if the dementia is severe, also some plaques.
In the olfactory epithelium (OE) and OB, the pathological 
changes are less conclusive (Table 1). Some studies suggest that 
one of the earliest degenerative events in AD is the involvement 
of the OB and the olfactory tract (Christen-Zaech et al., 2003). 
However, others suggest that dysfunction in higher cortical areas 
can correlate with olfactory deficits in AD, either in addition to or 
without pathologic changes in the OB and the OE (Masurkar and 
Devanand, 2014). There are studies suggesting that in AD, NFTs 
are not present in the OB, specifically the glomerular layer (GL), 
mitral cell layer (MCL), or GCL (Esiri and Wilcock, 1984), and 
are rare in mitral and tufted cells of the OB (Struble and Clark, 
1992). In contrast, other AD investigations have found NFTs in all 
layers of the OB except the outer fibrous layer (Ohm and Braak, 
1987), accompanied by Aβ deposition and neuropil threads in all 
layers of the OB (Kovács et al., 1999). Further, NFTs have been 
found in the OB and olfactory tract of cases with severe, discrete, 
and moderate cortical changes, suggesting an early involvement 
of the olfactory system in AD (Christen-Zaech et  al., 2003). 
Inconsistent findings have been reported in relation to plaques. 
Some studies failed to detect amyloid deposits (Struble and Clark, 
1992) or plaques (Ohm and Braak, 1987) in the OB, while others 
have shown the presence of plaques in the OB and tract, mostly in 
cases with severe cortical involvement from AD (Christen-Zaech 
et  al., 2003). Therefore, it appears that in human beings with 
AD, NFT burden in the OB is a more robust finding and is more 
consistent than the presence of amyloid plaques, particularly if 
the disease has not progressed to a severe level. This idea is sup-
ported by Braak staging, which suggests that plaque distribution 
can vary greatly between individuals, while NFTs have a more 
characteristic distribution pattern (Braak and Braak, 1991). 
Further, NFTs were present in almost all control cases between 
67.5 and 81.1  years of age, suggesting that NFTs are an earlier 
TABLe 1 | Pathological changes in various areas in AD cases.
Diagnosis Area NFTs Plaques Neuropil threads Age (years) N Reference
AD Entorhinal cortex Y Y 61–89 10 Reyes et al. (1993)
Prepiriform cortex Y Y
Periamygdaloid nucleus Y Y
Olfactory bulb and tract Y Y
AD Olfactory bulb Y X Y 57–63 4 Ohm and Braak (1987)
Anterior olfactory nucleus Y Y Y
Very mild/mildly demented Anterior olfactory nucleus Y Y 78–95 6 Price et al. (1991)
Entorhinal cortex Y Y
More severely demented Anterior olfactory nucleus Y Y 68–87 6
Entorhinal cortex Y Y
AD Anterior olfactory nucleus Y Y 61–85 10 Struble and Clark (1992)
Olfactory bulb Rare X
AD Anterior olfactory nucleus Y NA 64–91 6 Esiri and Wilcock (1984)
Olfactory bulb X NA
Discrete AD Olfactory bulb and tract Y X Y 44–93 58 Christen-Zaech et al. (2003)
Moderate AD Olfactory bulb and tract Y X Y 53–90 14
Severe AD Olfactory bulb and tract Y Y Y 44–93 19
AD Olfactory bulb Y Y (Aβ deposits) 74.8 (mean) 15 Kovács et al. (1999)
Anterior olfactory nucleus Y Y (Aβ deposits)
Y = present, X = not present, NA = not reported/assessed.
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pathological hallmark and that plaques may not present until AD 
progresses (Kovács et al., 1999).
One consideration is the recent in vitro and in vivo research 
suggesting that oligomeric Aβ may contribute to the neurotoxic 
events in early AD (Kirkitadze et al., 2002). For example, in rats, 
injections of conditioned medium containing soluble oligomeric 
Aβ transiently disrupted cognitive function (Cleary et al., 2005). 
In human AD cases, fibrillar oligomers are elevated and positively 
correlated with cognitive decline and neuropathological indices 
of amyloid plaque and tau tangle staging (Tomic et  al., 2009). 
However, in the olfactory system, soluble fibrillar oligomers were 
not elevated in the OB of AD cases and were only higher in the 
OB of normal controls compared to other brain regions (Tomic 
et al., 2009). Aβ expression has been identified as being signifi-
cantly more likely to be present in the OE of AD cases compared 
to normal cases or those with other neurodegenerative disease 
(Arnold et al., 2010). These levels correlated highly with averaged 
cortical Aβ plaque ratings; however, questions were raised as to 
whether the Aβ identified was fibrillar, as inclusions were similarly 
immunolabeled with an antibody against the N-terminus of Aβ, 
as well as an antibody labeling soluble oligomers (Arnold et al., 
2010). Despite the evidence regarding oligomeric Aβ, fibrillar Aβ 
is likely to still play a role in AD (Cleary et al., 2005).
As detailed earlier, the olfactory system has well-defined 
connectivity both within the system and with other cortical 
regions. Research has previously suggested that neurodegenera-
tive diseases, such as AD, target specific networks in the brain 
(Seeley et al., 2009). For example, the default mode hypothesis 
suggests that there is a relationship between default activity 
patterns in cortical regions and amyloid deposition in later life 
(Buckner et  al., 2005). However, activity may not be the only 
determinant of network vulnerability. The connectivity within 
brain networks may partly explain the spread of neurodegen-
eration. Specifically, it has been proposed that there may be 
transneuronal transmission of pathology (Kapogiannis and 
Mattson, 2011). Based on the findings of studies investigating 
pathological changes in the olfactory system and connected 
areas, it is logical that the olfactory system is particularly suited 
to investigating mechanisms operating in a neuronal network 
that may drive neuronal vulnerability in AD. The olfactory 
system provides a novel approach to investigate the role of 
activity and connectivity on the spread of AD pathology, on a 
background of aging-related changes.
ReSeARCH iNTO THe iNvOLveMeNT OF 
THe OLFACTORY SYSTeM iN MOUSe 
MODeLS OF ALZHeiMeR’S DiSeASe
Mouse models of AD allow the investigation of the effects of 
the disease and pathological changes in the olfactory system. 
Several mouse models of AD have been developed, includ-
ing, for example, Tg2576, APP/PS1, and 5XFAD lines, with all 
models being based on the overexpression of a single or multiple 
amyloidogenic mutant human genes (Masurkar and Devanand, 
2014). For example, Tg2576 mice overexpress a mutant form of 
human amyloid precursor protein (APP) containing a Swedish 
mutation (Hsiao et al., 1996), whereas APP/PS1 mice are double 
transgenic, expressing mutated forms of the APP and presenilin 1 
(PS1) genes (Radde et al., 2006). However, there are some limita-
tions to consider when using mouse models of AD and relating 
the findings back to human beings. For example, the temporal 
progression of the disease does not correlate well to AD in human 
beings (Masurkar and Devanand, 2014). Despite this, mouse 
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models can still provide important insights into changes in the 
olfactory system in relation to AD-like pathology.
In the OE, olfactory receptor neurons (ORNs) have been shown 
to be impacted in mouse models of AD. For example, OMP-hAPP 
mice expressing APP in only mature ORNs or Gγ8-hAPP mice 
expressing APP in immature ORNs show apoptosis in the OE despite 
an absence of extracellular plaques (Cheng et al., 2011). Further, in 
5XFAD mice, which are APP/PS1 mice that coexpress five familial 
AD mutations (Oakley et al., 2006), the olfactory nerve terminals 
are vulnerable to degeneration and this is associated with increased 
expression of amyloidogenic proteins prior to plaque appearance. 
This mouse model also demonstrated a decrease in glomerular area 
(Cai et al., 2012). Overall, studies propose ORN axonal dysfunc-
tion is involved in the activity-dependent pathophysiology of OB 
function by means of soluble Aβ (Masurkar and Devanand, 2014). 
Within the OB, non-fibrillar Aβ deposition has been observed in 
Tg2576 mice earlier than within any other brain area (Wesson 
et  al., 2010a), supporting the proposition that the human OB is 
damaged very early in the disease progression (Kovács et al., 2001). 
Further, interneuron markers, such as somatostatin and calretinin, 
are also reduced in the OB and AON in APP/PSI mice (Saiz-
Sanchez et al., 2013). This is consistent with the finding that, in APP 
mutant mice, increased Aβ production impairs neurogenesis in the 
subventricular zone (SVZ) (Haughey et al., 2002). Consequently, 
fewer interneurons, both periglomerular cells (PGCs) and granule 
cells (GCs), are generated via the rostral migratory stream (RMS) 
originating from the SVZ (Mobley et al., 2014).
Higher order cortical areas involved in olfaction also dem-
onstrate pathological changes in AD mouse models. Specifically, 
the amount of Aβ deposition has been shown to be notably 
greater within principal olfactory areas, such as the OB and the 
PCX, when compared to the primary somatosensory and motor 
cortices (Wesson et al., 2010a). Other findings demonstrate that 
TAPP and Tg2576 mice display plaques in the olfactory cortex, 
cingulate gyrus, amygdala, entorhinal cortex, and hippocampus 
at only 6 months of age, becoming numerous in older mice (Lewis 
et al., 2001). TAPP mice were created by crossing Tg2576 mice 
with a line that develop tau-labeled inclusions (JNPL3), with tau-
labeled inclusions being observed in the olfactory cortex, entorhi-
nal cortex, and amygdala of TAPP mice as early as 6 months of 
age (Lewis et al., 2001). Similarly, 5XFAD mice first demonstrate 
plaques in deep layers of the cortex, whereas older mice develop 
amyloid deposits in the cortex, subiculum, and the hippocampus 
as well. Plaques were also present in the OB in the older mice, 
but to a lesser extent (Oakley et al., 2006), which is similar to that 
in human cases. From these findings, it is clear that in mouse 
models of AD, there are numerous pathophysiological changes 
in the olfactory system and connected areas.
iNSiGHT iNTO MeCHANiSMS OF 
ALZHeiMeR’S DiSeASe PATHOGeNeSiS 
USiNG THe OLFACTORY NeTwORK AS A 
MODeL
When considering findings from both human and animal stud-
ies of olfactory dysfunction in normal aging and AD, the results 
suggest that the olfactory system clearly displays physiological 
changes in both normal aging and in AD. In particular, in mouse 
models of AD, the olfactory system (specifically the OB) is vul-
nerable to early pathological hallmarks, such as the deposition 
of Aβ (Wesson et al., 2010a). According to the amyloid cascade 
hypothesis of AD pathogenesis (Hardy and Higgins, 1992), Aβ 
deposition in the brain triggers a series of events that ultimately 
leads to the development of the disease (Karran et al., 2011). For 
example, major downstream effects of Aβ deposition include 
synaptic and neuronal loss (Selkoe, 1991), as well as disruption 
to spontaneous activity of brain areas (Beker et al., 2014). This 
dysfunction is postulated to propagate to downstream neurons 
within the recurrent network (Beker et  al., 2014), highlighting 
the idea that the olfactory system provides an ideal network for 
investigating mechanisms of AD pathogenesis.
Early symptoms of olfactory deficits in AD may stem from Aβ 
deposition in the OB, which then spreads progressively to con-
nected cortical areas (Kovács et al., 2001; Wesson et al., 2010a). 
This may be particularly true if the connected areas are ener-
getically challenged, such that these regions experience elevated 
excitation under oxidative stress or conditions of age-related 
impairment (Kapogiannis and Mattson, 2011). One hypothesis 
of the spread of AD pathology arose from the similarities to 
prion disease (Jucker and Walker, 2011). This is the view that 
AD pathology may be driven by progressive seeded aggregation 
of misfolded proteins, which spreads to interconnected neurons 
(Brettschneider et al., 2015). Support for a prion-like mechanism 
of transmission comes from findings that Aβ deposition can be 
induced by injection of brain extracts from human AD patients 
in mice that do not normally develop deposits (Morales et  al., 
2012). In this study, Aβ deposits were found in the cortex, far 
from the original injection site of the hippocampus. Thus, overall, 
connectivity may contribute to the spread of pathology in AD.
Deposition of Aβ in the OB is one of the earliest pathological 
changes in the olfactory system in the Tg2576 mouse model of 
AD (Wesson et  al., 2010a). It has been shown that the level of 
olfactory behavioral dysfunction was strongly correlated with 
the amount of Aβ deposition in mouse models, specifically in 
a spatial and temporal manner (Wesson et  al., 2010b). While 
Pittsburgh Compound B (PiB) PET scanning in human beings 
has shown that olfactory deficits in odor identification due to 
AD are not directly related to Aβ burden (Bahar-Fuchs et  al., 
2010), odor discrimination, and sensitivity were not investigated 
in this study. Further, it has been hypothesized that soluble Aβ 
oligomers may be the sole neurotoxic entity, although insoluble 
Aβ cannot be disregarded entirely (Haass and Selkoe, 2007). It 
has been demonstrated that soluble Aβ disrupts the OB network 
activity and olfactory function. For example, application of Aβ to 
OB slices of rodents resulted in decreased network activity of the 
OB at the GCL, in a concentration- and time-dependent manner 
(Alvarado-Martinez et al., 2013). Further, intrabulbar injections 
of Aβ resulted in decreases in olfactory function for at least 
2 weeks, beginning 2 weeks after the application. It was also found 
that the OB is more sensitive to the effects of Aβ with increasing 
age (Alvarado-Martinez et  al., 2013). Inversely, reducing the 
levels of soluble Aβ has been shown to restore olfactory cortical 
physiology and olfactory habituation ability (Wesson et al., 2011). 
TABLe 2 | Changes in AD-related pathology due to olfactory denervation.
Findings Method of 
denervation
Species Model Age of 
treatment
Reference
Increased beta-amyloid levels in hippocampus and neocortex. Bulbectomy Bilateral Mice WT 6 months Aleksandrov et al. 
(2004)
Increased tau phosphorylation in hippocampus. Bulbectomy Bilateral Mice Htau 3 months Li et al. (2014)
Increased BACE1 levels and amyloid deposition in the OB and 
piriform cortex.
Naris occlusion Unilateral Mice Tg2576 6 months Zhang et al. (2010)
Increased BACE levels in deprived bulb. Naris cauterization Unilateral Rats Sprague-
Dawley
? Yan et al. (2007)
Decreased plaque load in ipsilateral OB and bilateral neocortex/
hippocampus.
Triton X-100 Unilateral Mice APP/PS1
WT
2–3 months Bibari et al. (2013)
Increase in APP positive cells in WT denervated OB.
WT = wild-type.
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Consequently, it is important to conduct further investigations to 
determine how Aβ may lead to olfactory dysfunction, as studies 
regarding the cellular mechanisms involved may provide insight 
into potential targets for therapy.
AMYLOiD-β AND ALTeRATiON OF 
SYNAPTiC ACTiviTY
It has been postulated that Aβ may play a crucial role in synaptic 
decline, specifically Aβ may be involved in controlling neuronal 
activity at specific synaptic types or neuronal networks (Palop and 
Mucke, 2010). This may be a reciprocal relationship, as neuronal 
activity has been shown to regulate the level of interstitial fluid 
(ISF) Aβ (Cirrito et al., 2005; Bero et al., 2011). This has led to 
the notion that Aβ is part of a feedback loop controlling neuronal 
excitability. For example, increased neuronal activity produces 
more Aβ, which in turn depresses synaptic function resulting in 
decreased neuronal activity (Kamenetz et al., 2003). High levels 
of Aβ would, therefore, act to suppress neuronal activity, while it 
has been suggested that intermediate levels of Aβ may enhance 
synaptic activity (Palop and Mucke, 2010). These findings may 
correspond to the observations that advanced stages of AD are 
linked to decreased neuronal activity (Swaab et al., 1998), while 
early stages or even prodromal stages of the disease are associated 
with hyperactivity (Zilberter et al., 2013).
In normal circumstances, Aβ is present in a soluble form in 
the ISF of the brain throughout life. These levels of extracellular 
Aβ are the precursor to Aβ aggregation and AD pathogenesis 
(Cirrito et al., 2005). Animal studies indicated that regional ISF 
levels in young mice are predictive of the regional amyloid plaque 
deposition in aged mice (Bero et al., 2011). There is also increas-
ing evidence that Aβ levels can be modulated by synaptic activity. 
For example, ISF Aβ levels were shown to be directly influenced 
by synaptic activity, specifically synaptic vesicle release (Cirrito 
et  al., 2005). This study postulated that it may be possible for 
physical and environmental changes to alter neuronal or synaptic 
activity in a region-dependent manner, thus modulating the level 
of Aβ that can accumulate in plaques.
Studies have been conducted to alter sensory input to deter-
mine what effect this may have on ISF Aβ levels. For example, 
using a Tg2576 mouse model of AD, unilateral vibrissae 
deprivation resulted in reduced ISF Aβ levels in the barrel cortex, 
whereas unilateral vibrissae stimulation increased ISF Aβ levels 
(Bero et al., 2011). Further, long-term unilateral vibrissae dep-
rivation resulted in reduced levels of amyloid plaque formation 
and growth (Bero et al., 2011), suggesting that sensory input may 
modulate extracellular Aβ levels, impacting on the development 
of Aβ-related pathological hallmarks. In support of this, another 
study using an AD mouse model employed unilateral ablation of 
whiskers and chronic diazepam treatment to establish a chronic 
reduction of synaptic activity (Tampellini et  al., 2010). Barrel 
cortices with decreased activity showed a decreased number of 
Aβ plaques and the area they covered. There was also an increase 
in Aβ42 immunoreactivity within neurons, but a decrease in the 
levels of synaptophysin, which may have reflected a decrease in 
the number of synapses (Tampellini et  al., 2010). Surprisingly, 
despite a reduction in plaque load, spatial memory performance 
of mice undergoing the diazepam treatment continued to dete-
riorate. Therefore, while reducing sensory input may reduce Aβ 
pathology, it may not have any effect on behavior.
SeNSORY DePRivATiON OF OLFACTORY 
SYSTeM
Many studies have experimentally manipulated synaptic activity 
of the olfactory system through various methods of deprivation, 
such as peripheral deafferantation, olfactory bulbectomy (OBX), 
and naris occlusion. The majority of these studies have focused 
on structural changes in the OB or neurogenesis (e.g., Couper 
Leo et al., 2000a,b; Ducray et al., 2002; Mandairon et al., 2003, 
2006). In contrast, there have only been a few investigations of 
changes in AD-related pathology as a result of olfactory denerva-
tion (Table 2). Furthermore, these latter studies have produced 
some conflicting results. While studies on vibrissae deprivation 
and reduced activity in the barrel cortices indicate decreased ISF 
Aβ levels (Bero et al., 2011) and reduced plaque load (Tampellini 
et al., 2010), functional deprivation by unilateral naris occlusion 
in rats has been reported to result in an overproduction of Aβ in 
wild-type animals (Yan et  al., 2007). This was postulated to be 
mediated by increased BACE protein levels, β-site cleavage activ-
ity, and Aβ40 levels in the deprived OB of wild-type rats, as there 
was no detected change in gamma-secretase (Yan et  al., 2007). 
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Similarly, functional deprivation in a transgenic mouse model 
of AD lead to a significant increase in BACE1 levels in the OB 
and PCX (Zhang et al., 2010). It is thought that this increase may 
facilitate amyloid plaque formation, supported by the increase 
in amyloid deposition, but not before the age that global plaque 
onset occurs in Tg2576 mice regardless of these levels (Zhang 
et al., 2010). These studies used naris cauterization to achieve sen-
sory deprivation of the olfactory system. However, although this 
method results in structural changes, such as smaller ipsilateral 
OB size in adult rodents, it is argued that this method cannot 
achieve complete sensory deprivation [see Coppola (2012), for a 
review]. For example, studies demonstrating attenuated activity 
of specific cells in the OB after unilateral occlusion suggest that 
odors may pass into the contralateral nasal cavity (Philpot et al., 
1997).
An alternative method of olfactory denervation that results 
in greater sensory deprivation is OBX, which results in perma-
nent loss of olfactory function (Mucignat-Caretta et  al., 2006). 
Originally used in rodents as a model of depression (Kelly et al., 
1997), it has also been shown to result in learning and memory 
impairments in rodents (e.g., Hozumi et  al., 2003; Mucignat-
Caretta et al., 2006; Yehuda and Rabinovitz, 2013). Thus, it was 
suggested that it is possible to produce an animal model of AD 
by using OBX, as the technique results in effects similar to AD 
symptoms (Yehuda and Rabinovitz, 2013). For example, mice 
that received a bilateral OBX at 6 months showed spatial memory 
deficits on the Morris water maze 6  weeks after the operation 
(Aleksandrov et al., 2004). Bilateral OBX in mice has also been 
shown to increase AD-related pathology. For example, as well 
as demonstrating spatial memory deficits, wild-type mice that 
received a bilateral OBX also showed increased levels of Aβ in 
the neocortex and hippocampus. This occurred around the same 
time as the onset of spatial memory deficits, reaching a level 
comparable to the concentrations seen in transgenic APP mice 
with early-stage plaque formation (Aleksandrov et  al., 2004). 
However, while Aβ levels increased further in older transgenic 
mice, a similar level of Aβ was not reached in wild-type OBX mice 
(Aleksandrov et  al., 2004). Another study employing bilateral 
OBX in a human tau mouse model showed that OBX increased 
both hyperphosphorylation and insolubility of tau in the hip-
pocampus, suggesting that olfactory deprivation may hasten tau 
pathology (Li et al., 2014).
In contrast to the findings from the aforementioned studies 
proposing that olfactory deprivation using unilateral naris occlu-
sion or bilateral OBX result in increased pathological changes, 
a recent study using a Triton X-100 solution to unilaterally 
denervate the OB found decreased AD-related pathology (Bibari 
et al., 2013). Triton X-100 is a method of OB denervation that 
has been used by many studies focused on structural changes 
following denervation rather than changes to AD-related pathol-
ogy (e.g., Nadi et al., 1981; Verhaagen et al., 1990; Herbert et al., 
2012). It has been shown that Triton X-100 selectively destroys 
mature ORNs and their projections, while leaving the remaining 
olfactory mucosa intact (Cummings et al., 2000). Therefore, it is 
a method of reversible peripheral deafferentation, in which the 
pattern of axon reinnervation from the OE to the OB begins to 
resemble control patterns after only 3 weeks (Cummings et al., 
2000). APP/PS1 mice receiving repeated unilateral Triton X-100 
nasal washes were found to have decreased plaque load in the 
ipsilateral OB and bilaterally in the neocortex and hippocampus 
(Bibari et  al., 2013). Further, there was also an increase in the 
number of APP positive cells in the denervated bulb of wild-type 
mice, but not APP/PS1 mice, which could be due to pre-existing 
high levels of APP in the transgenic mice (Bibari et al., 2013). The 
findings of this study could be a consequence of downregulation 
in synaptic activity. Further research, particularly employing a 
bilateral method of denervation, is required to gain insight into 
the underlying mechanisms.
The differences in findings between the unilateral naris occlu-
sion and bilateral OBX relative to the unilateral chemical denerva-
tion of the OB may be partly explained by the different methods of 
sensory deprivation. It has been argued that nasal occlusion leads 
to ORNs remaining viable, with increased immunoreactivity for 
olfactory marker protein (OMP) in the deprived bulb, labeling 
mature ORNs (Waguespack et al., 2005). Further, there are also 
increased levels of olfactory-specific adenylyl cyclase, which is 
activated by odorants as part of olfactory transduction (Coppola 
et  al., 2006). Compared to Triton X-100, OBX is a large surgi-
cal insult that results in loss of olfactory inputs to other regions 
(Mucignat-Caretta et al., 2006). Findings from studies employing 
OBX may be due to the anterograde degeneration of neurons in 
brain regions that in normal conditions receive projections from 
the OB (Harkin et  al., 2003). Further, OBX may also involve 
destruction of centrifugal innervation from several parts of the 
brain, including hippocampal structures and the olfactory cortex 
(De Olmos et al., 1978; Luskin and Price, 1983). The finding that 
OBX may increase β-amyloid levels in mice (Aleksandrov et al., 
2004) may be due to damage to the brain. For example, in human 
beings, traumatic brain injury has been shown to accelerate Aβ 
deposition (Sivanandam and Thakur, 2012) and levels of Aβ42 
in the CSF (Raby et  al., 1998). As OBX removes the OB in its 
entirety, this method may not be ideal to investigate the role of 
connectivity within the olfactory system on AD pathogenesis, as 
the OB are a key component of this system. Additionally, findings 
of upregulation of BACE1 and accelerated amyloid deposition 
due to unilateral naris occlusion may be a result of compensa-
tory upregulation of different molecular components from the 
olfactory transduction pathway, possibly as a result of increased 
activation of the non-occluded side of the OB (Bibari et al., 2013). 
Therefore, peripheral deafferentation using Triton X-100 may be 
a better approach to investigate AD-related changes in the olfac-
tory network system.
OLFACTORY STiMULATiON
While there are multiple studies investigating the effects of 
olfactory deprivation on AD-related pathology, there are limited 
studies investigating the effect of olfactory stimulation. While 
olfactory stimulation studies exist (e.g., Rochefort et  al., 2002; 
Mandairon et  al., 2011; Bonzano et  al., 2014), only a few have 
a particular focus on AD-related pathology. Liao et  al. (2012) 
showed that short-term olfactory enrichment (40 days) did not 
alter the levels of tau phosphorylation in rats, while long-term 
(80 days) olfactory enrichment attenuated the phosphorylation 
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of tau in areas of the hippocampus and cortex; the effect of odor 
enrichment on the OB was not examined (Liao et al., 2012). Due 
to the shortage of studies primarily focusing on the effect of 
olfactory stimulation on AD-related pathology in the olfactory 
system, future studies should investigate these effects employing 
the odor enrichment protocols from previous studies.
It is relevant to investigate the effects of olfactory stimulation or 
enrichment because it can be regarded as an aspect of environmen-
tal enrichment. It has been argued that environmental enrichment 
leads to neural changes, for example, increase in synaptogenesis 
and cell survival in neurogenesis (van Praag et al., 2000). Further, 
passive exposure to odors results in behavioral changes, such as 
improving olfactory discrimination (Mandairon et  al., 2006), 
suggesting that physiological changes induced by enrichment can 
be translated into behavioral changes. Consequently, such neural 
changes may also modulate Aβ amyloidgenesis. While some 
studies have demonstrated that environmental enrichment may 
lead to increased amyloid burden in transgenic mice (Jankowsky 
et al., 2003), it may also build resistance to the negative effects 
of Aβ (Jankowsky et al., 2005). Further, studies using transgenic 
mice have shown that environmental enrichment can lead to 
decreases in the levels of steady state cerebral Aβ peptides and 
amyloid deposition (Lazarov et al., 2005). Therefore, there may 
be a connection between synaptic activity, APP processing, and 
Aβ production, which is modulated by environmental enrich-
ment. Conversely, it has also been hypothesized that increased 
synaptic activity from enrichment may increase susceptibility 
to Aβ deposition if there are high levels of APP present (Cirrito 
et  al., 2005). This is an important hypothesis to test using the 
olfactory system, as previously, it has been demonstrated using 
electrophysiological techniques that in an AD mouse model, the 
OB experiences hyperactivity in early life (Wesson et al., 2011). 
This hyperactivity corresponds to Aβ deposition restricted to 
the OB and may increase PCX activity, thus leading to impaired 
olfactory perception. Later in life, PCX dysfunction corresponds 
to hypoactivity, perhaps due to upregulation of Aβ production 
in both the OB and PCX (Wesson et al., 2011). These findings 
highlight that connectivity, as well as activity, of the olfactory 
system may play some role in Aβ deposition. It has also been 
suggested that Aβ can lead to GABAergic dysfunction, which may 
contribute to aberrant synchrony in neural networks, translating 
to disruption of cognitive functions (Palop and Mucke, 2010). 
The organization of newly generated inhibitory interneurons and 
their connections may be directed by OB activity, as their survival 
is upregulated by odor exposure (Rochefort et al., 2002). Thus, the 
effect of environmental enrichment, such as odorant stimulation 
on AD pathology, is a complex issue that is poorly understood 
and warrants further investigation.
OLFACTORY DYSFUNCTiON AND 
ALZHeiMeR’S DiSeASe PATHOLOGY
While the causal relationship between Aβ and olfactory dysfunc-
tion remains somewhat unclear, it may be an interactive relation-
ship, rather than a one-way effect. For example, increased Aβ may 
drive olfactory dysfunction, but olfactory dysfunction may also 
result in increased Aβ production. Further, it is worthwhile to 
consider the interactive effects of NFTs, which may also influence 
olfactory dysfunction in AD. Not only have decreases in olfactory 
function been shown in mice overexpressing tau (Macknin et al., 
2004), but also tau pathology has been reported in the olfactory 
system of individuals with AD. For example, studies have identified 
tau pathology in the OB and olfactory tract (Attems and Jellinger, 
2006), and the AON (Esiri and Wilcock, 1984; Tsuboi et al., 2003), 
even in early stages of the disease (Tsuboi et  al., 2003; Attems 
and Jellinger, 2006). The olfactory system presents an ideal model 
to address these issues, specifically aiding in the investigation of 
the network-driven mechanisms of AD pathogenesis, potentially 
through altering sensory input in mouse models of AD.
SeNSORY iNPUT AND NeUROGeNeSiS
The olfactory system is unique, as even in adulthood, related neu-
ral regions have the ability to regenerate. While not demonstrated 
in human studies, transgenic mouse models of AD have shown 
that cell proliferation and neurogenesis is impaired, particularly 
in the SVZ (Rodriguez and Verkhratsky, 2011). Neurogenesis 
occurs in two regions of the olfactory system – peripherally in 
the OE (Schwob, 2002) and centrally in the OB (Haughey et al., 
2002). Even into adulthood, the OE contains a population of 
proliferating progenitor cells (Schwob, 2002). ORNs continually 
grow, die, and regenerate in a cycle lasting 30–60 days (Sultan-
Styne et al., 2009). Mature ORNs degenerate due to nerve injury 
or from exposure to environmental agents that enter the nasal 
cavity. The degenerated neurons are replenished by continuous 
neurogenesis among the basal cells of the OE (Huard and Schwob, 
1995). Not only do ORNs regenerate in adult animals, there is 
also continual generation of new interneurons (PGCs and GCs) 
in the adult brain (Mobley et al., 2014), which are predominately 
GABAergic inhibitory interneurons (Parrish-Aungst et  al., 
2007). As well as peripheral neurogenesis in the olfactory system, 
neurogenesis occurs centrally in the OB, which receives newly 
generated neurons from the SVZ. The OB is connected to the SVZ 
by a large migratory pathway known as the RMS (Lledo et al., 
2008). While the RMS was originally difficult to define in human 
beings, recent findings suggest that the adult human RMS is actu-
ally similar to other species, including the rat (Kam et al., 2009). 
The SVZ contains stem cells that have the ability to proliferate 
and differentiate into neurons in the OB (Haughey et al., 2002). 
Specifically, cells migrate to the GCL or GL to differentiate into 
interneurons (Luskin, 1998).
There is increasing evidence to suggest that alterations to 
sensory input can modulate neurogenesis in the adult OB. 
Specifically, sensory deprivation by axotomy of mature ORNs 
to produce unilateral reversible deprivation in wild-type mice, 
revealed an increase in both cell death and proliferation in the 
SVZ, RMS, and OB within the first 2  weeks of denervation, 
returning to levels of controls after 1 month (Mandairon et al., 
2003). However, it has been suggested that it is not merely olfac-
tory exposure that alters neurogenesis; rather olfactory learning 
is responsible (Alonso et al., 2006). This has been supported by 
findings that demonstrate learning of an odor discrimination task 
increased the number of newly generated cells in the deep, but 
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not superficial, GCL. Further, there was a critical period between 
18 and 30 days when new cells were more likely to survive, cor-
responding to the time when the new cells are starting to form 
glutamatergic synapses (Mouret et  al., 2008). Therefore, it may 
be that olfactory learning helps newly generated inhibitory 
interneurons in the OB to survive by altering synaptic connec-
tions. This is important to consider, as disruptions to the balance 
between the excitatory and inhibitory neurotransmitters in the 
brain (glutamate and GABA) are present in AD (Kapogiannis and 
Mattson, 2011). While studies such as these provide important 
models to investigate the effects of altering sensory input in the 
OB, it is also important to consider that not all cellular mecha-
nisms are dependent on sensory input.
SUMMARY
Overall, current evidence suggests that, in AD, specific networks 
in the brain may be more vulnerable to the pathology of the dis-
ease. They may provide a model for network-driven mechanisms 
of AD pathogenesis. The olfactory system is one such network 
that has been implicated in the early stages of AD. Not only have 
pathological hallmarks been identified in this system, but they 
are also prevalent in connected cortical regions, well known for 
their involvement in AD. While connectivity may help to explain 
the development or progression of the disease, alterations to 
neuronal activity have also been suggested as being involved, 
particularly in relation to amyloid deposition. Although studies 
have begun investigating the impact of sensory alteration through 
denervation or enrichment, there has not been a heavy focus on 
AD-related changes, thus the mechanisms behind the disease 
pathogenesis remain elusive. This review has discussed the impli-
cations of connectivity and activity in the spread of pathology 
in AD and proposes that the olfactory system is a well-defined 
network that can be used to address these issues in future studies.
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